Prof. Dr. Dario Neri (CEO and CSO), Dr. Covelli (CMO), Dr. Dakhel, Dr. De Luca, Dr. Cazzamalli, Dr. Galbiati, Dr. Puca, Sara Puglioli. Matilde Bocci, Giulia Rotta, Eleonora Prodi and Aureliano Zana will participate at the event.

Moreover, the following abstracts have been accepted as Poster Presentations:

Eleonora Prodi – Tripokin: potential best-in-class for tumor targeted interleukin-2 (IL2) potentiated by tumor necrosis factor (TNF)

Dr. Galbiati – Tumor-targeted interleukin-2 enhances the anti-cancer activity of multivalent OncoFAP radioligand therapeutics

Matilde Bocci – Delivery of cytotoxic camptothecin derivatives to tumors by OncoFAP-based Small Molecule-Drug Conjugates

Sara Puglioli – DNA-encoded affinity maturation libraries enable the discovery of low picomolar Fibroblast Activation Protein inhibitors suitable for radioligand therapy of solid tumors

Aureliano Zana – FAP-targeted non-internalizing drug conjugates: a comparative evaluation between small molecules, antibodies and peptides

Giulia Rotta – Decreasing toxicity of immunocytokines by transient and selective inhibition of their intracellular signaling activation.

Please follow the link for more information